CAJ | 학술논문

目的：探讨 CT 灌注在局部晚期宫颈鳞癌新辅助化疗(NACT)疗效评价中的价值。方法67例 Ib2-IIb 期宫颈鳞癌患者于 NACT 前行 CT 灌注成像，测量血流量(BF)、血容量(BV)、达峰时间(MTT)、表面通透性(PMB)、灌注峰值时间(TTP)、MIP (HU)，于 NACT 2个疗程结束后行常规增强 CT 检查，测量肿瘤大小，评价疗效。结果67例患者中有效组48例(完全缓解2例，部分缓解46例)，无效组19例(病变稳定15例、病变进展4例)，总体有效率为71.6%。NACT 前，有效组与无效组 BV 及 PMB差异有统计学意义(P <0.001)，有效组与无效组化疗前 BF、MTT、TTP、MIP(HU)差异无统计学意义(P >0.05)，化疗有效患者的BV 值及 PMB 值相对较高。结论NACT 前可通过 CT 灌注成像测量肿瘤的 BV 及 PMB 值，为临床选择治疗方案提供依据。
목적：탐토 CT 관주재국부만기궁경린암신보조화료(NACT)료효평개중적개치。방법67례 Ib2-IIb 기궁경린암환자우 NACT 전행 CT 관주성상，측량혈류량(BF)、혈용량(BV)、체봉시간(MTT)、표면통투성(PMB)、관주봉치시간(TTP)、MIP (HU)，우 NACT 2개료정결속후행상규증강 CT 검사，측량종류대소，평개료효。결과67례환자중유효조48례(완전완해2례，부분완해46례)，무효조19례(병변은정15례、병변진전4례)，총체유효솔위71.6%。NACT 전，유효조여무효조 BV 급 PMB차이유통계학의의(P <0.001)，유효조여무효조화료전 BF、MTT、TTP、MIP(HU)차이무통계학의의(P >0.05)，화료유효환자적BV 치급 PMB 치상대교고。결론NACT 전가통과 CT 관주성상측량종류적 BV 급 PMB 치，위림상선택치료방안제공의거。
Objective To investigate the value of perfusion CT in the evaluation of neoadjuvant chemotherapy in locally advanced squamous cell carcinoma.Methods Sixty-seven patients with Ib2-IIb squamous cell carcinoma of the cervix underwent CT perfusion imaging before neoadjuvant chemotherapy to measure blood flow (BF),blood volume (BV),peak time (MTT),permeability sur-face (PMB),perfusion time to peak (TTP)and MIP(HU);and underwent routine enhancement CT after the two course of neoadju-vant chemotherapy treatment to measure tumor size,and evaluate the therapeutic effect.Results Among 67 patients,48 patents were effective (2 completely remission and 46 partial remission),and 1 9 patients were ineffective (1 5 stable and 4 progressed),with the overall response rate of 71.6%.The differences of PMB and BV value between effective and ineffective group were statistically significant before neoadjuvant chemotherapy (P <0.001).The BF,MTT,TTP value were no significant difference between effec-tive and ineffective group before neoadjuvant chemotherapy (P >0.05).The BV and PMB value were relatively higher in the patients with effective chemotherapy.Conclusion CT perfusion imaging could measure the BV and PMB value of the tumor before neoadju-vant chemotherapy to provide the basis for treatment selection.